Statement of Changes in Beneficial Ownership (4)
August 07 2020 - 7:07PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Kummeth Charles R. |
2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp
[
TECH
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Executive Officer |
|
(Last)
(First)
(Middle)
614 MCKINLEY PLACE NE |
3. Date of Earliest Transaction
(MM/DD/YYYY)
8/5/2020 |
|
(Street)
MINNEAPOLIS, MN 55413
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
| Common Stock | 8/5/2020 | | A | | 8586 | A | $0 | 152483 (1) | D | |
| Common Stock | | | | | | | | 100 | I | By Step-Son |
| Common Stock | | | | | | | | 100 | I | By Step-Daughter |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code
(Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) | 8. Price of Derivative Security
(Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Stock Options (Right to Buy) | $86.25 | | | | | | | (2) | 4/1/2021 | Common Stock | 25157 | | 25157 | D | |
| Stock Options (Right to Buy) | $94.35 | | | | | | | (2) | 8/12/2021 | Common Stock | 66849 | | 66849 | D | |
| Stock Options (Right to Buy) | $108.49 | | | | | | | (2) | 8/7/2022 | Common Stock | 95346 | | 95346 | D | |
| Stock Options (Right to Buy) | $108.49 | | | | | | | (2) | 8/7/2022 | Common Stock | 79517 | | 79517 | D | |
| Stock Options (Right to Buy) | $106.59 | | | | | | | (2) | 8/18/2023 | Common Stock | 154169 | | 154169 | D | |
| Stock Options (Right to Buy) | $106.59 | | | | | | | (3) | 8/18/2023 | Common Stock | 102779 | | 102779 | D | |
| Restricted Stock Units | (4) | | | | | | | (5) | (5) | Common Stock | 21291 | | 21291 | D | |
| Stock Options (Right to Buy) | $125.05 | | | | | | | (5) | 8/9/2024 | Common Stock | 117342 | | 117342 | D | |
| Stock Options (Right to Buy) | $125.05 | | | | | | | (6) | 8/9/2024 | Common Stock | 78228 | | 78228 | D | |
| Restricted Stock Units | (4) | | | | | | | (7) | (7) | Common Stock | 16918 | | 16918 | D | |
| Stock Options (Right to Buy) | $177.32 | | | | | | | (7) | 8/8/2025 | Common Stock | 90334 | | 90334 | D | |
| Stock Options (Right to Buy) | $177.32 | | | | | | | (8) | 8/8/2025 | Common Stock | 60222 | | 60222 | D | |
| Restricted Stock Units | (4) | | | | | | | (9) | (9) | Common Stock | 16937 | | 16937 | D | |
| Stock Options (Right to Buy) | $190.41 | | | | | | | (9) | 8/7/2026 | Common Stock | 85725 | | 85725 | D | |
| Stock Options (Right to Buy) | $190.41 | | | | | | | (10) | 8/7/2026 | Common Stock | 57150 | | 57150 | D | |
| Restricted Stock Units | (4) | 8/5/2020 | | A | | 12879 | | (11) | (11) | Common Stock | 12879 | $0 | 12879 | D | |
| Stock Options (Right to Buy) | $267.87 | 8/5/2020 | | A | | 57442 | | (11) | 8/5/2027 | Common Stock | 57442 | $0.0 | 57442 | D | |
| Stock Options (Right to Buy) | $267.87 | 8/5/2020 | | A | | 38295 | | (12) | 8/5/2027 | Common Stock | 38295 | $0 | 38295 | D | |
| Stock Options (Right to Buy) | $267.87 | 8/5/2020 | | A | | 16650.0 | | (13) | 8/5/2027 | Common Stock | 16650.0 | $0.0 | 16650.0 | D | |
| Stock Options (Right to Buy) | $267.87 | 8/5/2020 | | A | | 16650 | | (14) | 8/5/2027 | Common Stock | 16650 | $0.0 | 16650 | D | |
| Explanation of Responses: |
| (1) | Includes (i) 4,732 shares of restricted stock for which the risk of forfeiture will lapse on August 9, 2020; (ii) 7,519 shares of restricted stock for which the risk of forfeiture will lapse as to 3,760 shares on August 8, 2020 and as to 3,759 shares on August 8, 2021; (iii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iv) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. |
| (2) | Fully exercisable. |
| (3) | Options to purchase 25,695 shares vest on each of 8/18/2017, 8/18/2018 and 8/18/2019 and options to purchase 25,695 shares vest on 8/18/2020. |
| (4) | Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. |
| (5) | Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| (6) | Options to purchase 19,557 shares vest on each of 8/9/2018, 8/9/2019, 8/9/2020 and 8/9/2021. |
| (7) | Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| (8) | Options to purchase 15,056 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 15,055 shares vest on each of 8/8/2021 and 8/8/2022. |
| (9) | Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| (10) | Options to purchase 14,288 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 14,287 shares vest on each of 8/7/2022 and 8/7/2023. |
| (11) | Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| (12) | Options to purchase 9,574 shares vest on each of 8/5/21, 8/5/22 and 8/5/23 and options to purchase 9,573 shares vest on 8/5/24. |
| (13) | Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021 |
| (14) | Options to purchase 5,550 shares vest on each of 8/5/21, 8/5/22 and 8/5/23. |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
Kummeth Charles R.
614 MCKINLEY PLACE NE
MINNEAPOLIS, MN 55413 | X |
| Chief Executive Officer |
|
Signatures
|
| /s/ Brenda S. Furlow as Attorney-in-Fact for Charles R. Kummeth pursuant to Power of Attorney previously filed. | | 8/7/2020 |
| **Signature of Reporting Person | Date |
Bio Techne (NASDAQ:TECH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bio Techne (NASDAQ:TECH)
Historical Stock Chart
From Apr 2023 to Apr 2024
